Bibliografias temáticas / Hepatitis C

Índice

  1. Artigos de revistas
  2. Teses / dissertações
  3. Livros
  4. Capítulos de livros
  5. Trabalhos de conferências
  6. Relatórios de organizações

Literatura científica selecionada sobre o tema "Hepatitis C"

Autor: Grafiati
Publicado: 4 de junho de 2021
Última modificação: 31 de agosto de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Hepatitis C".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "Hepatitis C"

1

Nouman, Muhammad Khuram, Bushra Zaidi, Ghulam Mohiuddin, Faryal Asif e Muhammad Khan Malik. "HEPATITIS C". Professional Medical Journal 25, n.º 03 (10 de março de 2018): 387–91. http://dx.doi.org/10.29309/tpmj/2018.25.03.381.

Texto completo da fonte
Resumo:
Background: Hepatitis C virus (HCV) is the most communal source of non-A,non-B viral hepatitis in the world. The disease is illusory, and the majority of patients do notacquire jaundice at its onset. Treatment of hepatitis C with interferon attained a sustainedvirological response (SVR) in almost 50% of the patients with HCV infection. Viral genotype isimportant to determine the response. The present study aims to provide the incidence of relapseof HCV in patients taking interferon therapy and to identify the predictors for relapse. StudyDesign: Retrospective observational study. Setting: Department of Medicine, DHQ TeachingHospital, Sargodha. Period: Two years. Methods: A total of 60 patients were retrospectivelyevaluated for this study. The exclusion criteria include the patients co- infected with hepatitisB virus or HIV. All the patients were monitored 2, 4, 8, 12, 16, and 24 weeks after the endof treatment with interferon alpha. Results: We observed that the patients with relapse weresignificantly older and heavier (P value < 0.05). At the start of treatment, viral load was higherin relapsed patients (P value < 0.04). Conclusion: On the bases of our study findings, we canconclude that low incidence of relapse occurred with interferon therapy. High ALT level, viralloads, older age and obesity were some of strong predictors of relapse among HCV patients.
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Jamali, Ghulam Mustafa, Anwar Ali Jamali e Habibullah Shaikh. "HEPATITIS C VIRUS;". Professional Medical Journal 24, n.º 11 (3 de novembro de 2017): 1621–29. http://dx.doi.org/10.29309/tpmj/2017.24.11.646.

Texto completo da fonte
Resumo:
Objectives: The plan of this current research was in the direction for towards theassessment of the existing ELISA (Enzyme Linked Immunosorbant Assay) method throughantibodies testing for identification of hepatitis C virus disease by comparing their outcome withthe Real Time polymerase chain reaction analysis. Setting: Peoples Medical College HospitalNawabshah. Period: December 2015 to December 2016. Methods: In this current research 100blood samples were analyzed due to the presence of anti-HCV antibodies by 3rd-generationenzyme-linked immunosorbent assay testing. All the specimens were 100% positive. Polymerasechain reaction test was performed according to the laboratory directions in anti- hepatitis C virusantibodies positive patients to validate the diagnosis of hepatitis C virus infectivity. Results: Thisresearch shows that, the entire results were positive by Enzyme Linked Immunosorbant Assaytesting. As compared with polymerase chain reaction the of Enzyme Linked ImmunosorbantAssay in this research the screening test for anti hepatitis C virus - antibodies is about 2%false positive. Out of the 100 samples 98 cases are positive by Real Time polymerase chainreaction analysis while only 02 cases report are negative (2%). Conclusion: The proportion ofhepatitis C virus infectivity was 100% by 3rd-generation enzyme-linked immunosorbent assaytesting, 98% by Real Time polymerase chain reaction analysis. As in our research the hepatitisC virus –Ribonucleic acid is present in 98% cases who are the Anti- hepatitis C virus antibodiespositive patients, it can be suggested that Anti-HCV antibodies detection by third generationELISA technique in routine procedure is sufficient to determine HCV infection.
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Jain, Ravi, e Ashok Yadav. "Hepatitis B Versus Hepatitis C in Blood Donors". Annals of Applied Bio-Sciences 4, n.º 1 (janeiro de 2017): A8—A13. http://dx.doi.org/10.21276/aabs.2017.1306.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Billah, Mustansar, Syed Muhammad Raza Shah e Muhammad Mujtaba Hashir. "HEPATITIS B AND HEPATITIS C". Professional Medical Journal 25, n.º 08 (9 de agosto de 2018): 1245–51. http://dx.doi.org/10.29309/tpmj/18.4766.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

TARIQ, FAQIR MUHAMMAD, IRSHAD AHMAD, HABIB SUBHANI e Irshad Ul Haq. "HEPATITIS C". Professional Medical Journal 16, n.º 02 (10 de junho de 2009): 169–72. http://dx.doi.org/10.29309/tpmj/2009.16.02.2890.

Texto completo da fonte
Resumo:
I n t r o d u c t i o n : Hepatitis C is a RNA virus isolated in 1988 but still not cultured in the laboratory. Hepatitis-C infection is aserious global public health issue, WHO estimates worlds 3 % population is HCV positive. Pakistan is also facing the huge burden of thisdisease. Accurate prevalence information for hepatitis C infection is scant in Pakistan. Few population based studies are available, the mostcomprehensive being that of Luby et al which after testing a representative sample from a population of 150,000 in Hafizabad, Pakistanfound an overall sero-prevalence of 6%. This increased to 30% with increasing age. They also found sero-prevalence of 16% in householdmembers of HCV infected cases. Aslam et al reported a population prevalence of 16% from Lahore and 23.8% in Gujranwala. In our studypublished in Medical Forum showed prevalence of HCV antibodies in population attending our department of ophthalmology is 27.06%.There is no data from Pakistan about prevalence of hepatitis C in Paramedical staff. It appears that paramedical staff is at higher risk ofcontracting this infection as they are exposed to multiple risk factors like needle stick injuries. Little is known about the prevalence of HepatitisC in this group of population. The objective of our study was to assess the perceived increased incidence of Hepatitis C in this group ofpopulation. M e t h o d s & Materials:This is a retrospective audit of the data from the records kept by clinical laboratory of University MedicalCollege, Faisalabad. All paramedical staff members were invited for HCV antibody test on 13.1.2007 to 20.1.2007.Any staff member workingin those days was included in the study. Persons on holidays or did not give free informed consent was excluded from the study. Serumof blood samples were analyzed by EXCEL a one step test device for the qualitative detection of antibodies to Hepatitis C virus in serumor plasma by trained professional. This test has a relative sensitivity of 96.8%, relative specificity 99% and accuracy 98.9% as comparedto HCV EIA test. Statistical analysis was performed by SPSS system.Results: A total 80 staff members were working in the hospital at thattime, 61 attended for the test (F: 31, M: 30). We found 7 (11.4%) were HCV positive and 54 (88.52%) were HCV negative including 2 weeklypositive. Among HCV positive 4 (6.55%) were male and 3 (4.91 %) were females. Age distribution was 17 - 75 years with mean age 32.51years. Among HCV positive 3 were analyzed by ELISA technique. 2 weekly positive by EXCEL were negative by ELISA and 1 positive byEXCEL was positive by ELISA. C o n c l u s i o n : Paramedical staff is perhaps not at higher risk of contracting HCV infection. However morestudies are required to further assess this finding.
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Salam, Abdul, Bilqis Aslam Baloch, Naseer Khan, Ghulam Sarwar e Masoom ,. "SEROPREVALENCE OF HBsAg (HBS) AND ANTI-HCV". Professional Medical Journal 21, n.º 04 (7 de dezembro de 2018): 766–70. http://dx.doi.org/10.29309/tpmj/2014.21.04.2424.

Texto completo da fonte
Resumo:
Background: Hepatitis is the inflammation of liver caused by infectious and noninfectiousagents. Hepatitis B and C are inflammations of liver caused by the viruses which are themajor public health problems worldwide and the incidence is even more in our country.Objective: Objective of the study was, 1). To estimate the prevalence of hepatitis B and hepatitisC viruses infected persons among the general population coming to BMC Hospital. 2). To pointout the more affected area of Baluchistan. 3). To produce awareness in the people. 4). To bringthis issue in Government notice. Method: The data was obtained from the patients of BMCHQuetta in which one step test kits were used first and the positive cases were confirmed by ELISA.Results: Out of 46319 samples tested (both indoor & outdoor patients), 3078 (6.64%) werepositive. From overall positive samples 1631(3.52%) were HBs positive and 1447(3.12) sampleswere positive for HCV and 2 patients were positive for both HBs Ag and anti HCV. Conclusions:Prevalence of Hepatitis B is more comparing to Hepatitis C in this province. Prevalence of bothHepatitis B and Hepatitis C was high in Naseerabad district of Baluchistan Great care should beexercised during shaving, dental treatment, surgical procedures and blood transfusions. Policymessage: - Media should be used by National Hepatitis Control Programme of Pakistan toeducate the public about hazards of unscreened blood transfusion. Blood screening for HepatitisB and C infections should be made mandatory at all blood banks.
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Andrade, Luís Jesuino, Paulo Melo, Isabel Lins, Raymundo Paraná e Augusto Lins. "HEPATITIS C VIRUS AND HEPATITIS C-INFECTION". Brazilian Journal of Medicine and Human Health 3, n.º 1 (31 de maio de 2015): 19–28. http://dx.doi.org/10.17267/2317-3386bjmhh.v3i1.453.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Viana, Daniel Rodrigues, Nathalia Mundoco Veloso, Osvaldo Carvalho Neto, Nicolas Garcia Papacosta, Gabriel Martins Nunes e Virgílio Ribeiro Guedes. "Hepatite B e C: diagnóstico e tratamento". Revista de Patologia do Tocantins 4, n.º 3 (26 de setembro de 2017): 73. http://dx.doi.org/10.20873/uft.2446-6492.2017v4n3p73.

Texto completo da fonte
Resumo:
INTRODUÇÃO: As hepatites virais são consideradas as principais doenças hepáticas, podendo levar a quadros mais graves, como a cirrose e o carcinoma hepatocelular, tornando-se um importante problema de saúde pública. Tem distribuição global com áreas de altos índices de endemicidade, sobretudo em países asiáticos. Os principais agentes envolvidos são os vírus da hepatite A, B, C, D, E. O vírus da hepatite B e C se destacam nesse meio devido à grande capacidade de cronificação. As formas de transmissão são basicamente através do contato com fluidos corporais infectados, através de transfusões sanguíneas, uso de drogas injetáveis, transmissão vertical, etc. METODOLOGIA: Trata-se de um artigo de revisão no qual, a partir das palavras “hepatite B” e “hepatite C”, foi realizado busca por periódicos nos bancos de dados: PubMed, Scielo, Portal Periódicos CAPES e Google acadêmico. CONCLUSÃO: As hepatites B e C podem se apresentar apenas de forma aguda, ou podem se cronificar. O diagnóstico geralmente é realizado tardiamente, pois, na grande maioria dos casos apresenta-se oligossintomáticas ou até mesmo assintomática. O diagnóstico é feito através de exames sorológicos e quantificação viral através do PCR. O tratamento é basicamente sintomático, porem nos casos crônicos, é indicado uso de medicações, como interferons peguilhados e análogos de nucleosideos. Palavras-chave: Hepatites virais; Hepatite B; Hepatite C. INTRODUCTION: Viral hepatitis are considered as one of the major liver diseases, being able to lead more severe outcomes, such as cirrhosis and hepatocellular carcinoma becoming an important public health problem. It has global distribution with areas of high endemicity, especially in Asian countries. The main agents involved are hepatitis A virus, B, C, D, E. The hepatitis B and C viruses stand out in the middle of a chronicling ability. As the transmission forms are basically through contact with infected body fluids, through blood transfusions, injecting drug use, vertical transmission, etc. METHODOLOGY: This is a review article, from the words "hepatitis B" and "Hepatitis C", was carried out by search for journals in databases: PubMed, Scielo, Portal Periodicos CAPES and Google academic. CONCLUSION: The hepatitis B and C can either be only a form of acute, or can be chronic. Therefore, the diagnosis is often late, since in the vast majority of cases it is oligosymptomatic or even asymptomatic. The diagnosis is made through serological tests and viral quantification through PCR. The treatment is basically with symptomatic, such as pegged interferon’s and nucleoside analogs. Keywords: Viral hepatitis; Hepatitis B; Hepatitis C.
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Moradpour e Blum. "Hepatitis C". Therapeutische Umschau 61, n.º 8 (1 de agosto de 2004): 493–98. http://dx.doi.org/10.1024/0040-5930.61.8.493.

Texto completo da fonte
Resumo:
Die Infektion mit dem Hepatitis C Virus (HCV) ist weltweit eine der häufigsten Ursachen der chronischen Hepatitis, Leberzirrhose und des hepatozellulären Karzinoms. In diesem Beitrag werden der aktuelle Stand und neue Entwicklungen auf dem Gebiet der Virologie, Diagnostik und Therapie der Hepatitis C zusammenfassend dargestellt. Die Standardtherapie der chronischen Hepatitis C mit pegyliertem Interferon-alpha und Ribavirin führt bei etwa 40–50% der Genotyp 1- und rund 80% der Genotyp 2 und 3-infizierten Patienten zur anhaltenden Viruselimination. Aufbauend auf einem verbesserten Verständnis der molekularen Virologie und Pathogenese der Hepatitis C werden heute neue antivirale Strategien exploriert, die wahrscheinlich schon in naher Zukunft die bestehenden therapeutischen Modalitäten ergänzen werden.
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Khan, Momin, Abdul Jabbar, Bacha Amin Khan, Abdul Ahad e Fazal Akbar. "HEPATITIS C". Professional Medical Journal 25, n.º 04 (10 de abril de 2018): 484–88. http://dx.doi.org/10.29309/tpmj/2018.25.04.332.

Texto completo da fonte
Resumo:
Introduction: WHO estimates that there are more than 185 million people overthe globe infected with hepatitis C. Among these 350,000 die each year with hepatitis. Heprevalence of hepatitis in Asia is estimated to be 3.4%. Pakistan has been rated as the secondmost common country in the world with active hepatitis C infection. This study aims at identifyingthe frequency of risk factors for hepatitis C irus transmission. Understanding the frequency ofcommon factors of HCV would help to implement strategies in long-term prevention of hepatitistransmission among community. Objectives: To determine the frequency of common factorsfor transmission of hepatitis C in adult patients. Study Design: Descriptive cross-sectionalstudy. Setting: Department of Medicine, Saidu Teaching Center, Swat. Period: 01-01-2016 to01-12-2016. Methodology: 140 patients were observed and evaluated. Detailed medical historywas taken.5 ml of venous blood sample was collected under aseptic conditions. Blood wascentrifuged at 5000 rpm for 5 minutes and serum was transferred to separate test tubes for furthertesting. The initial screening was carried out by immunochromatography for the qualitative detectionHCV antibodies in serum or plasma. Output variable was stratified among age andgender. Chi square test was applied to see effect of modification. All the positive samples onICT were tested on ELISA (third generation) with signal-to-cut-off ratio > 1.0 for confirmation.Results: Our study shows that mean age was 45 years with SD ± 12.24. Fifty eight percentpatients were male and 42% patients were female. Forty two percent patients had hepatitis Cdue to Injection, infection and-* /transfusions, surgical scars were present in 23% patients withhepatitis C, (2%) patients with hepatitis C had tattoos, 8% patients had hepatitis C due to nose/ear piercing and 25% patients had hepatitis C due to dental procedures. Conclusion: Our studyconcludes that the most common risk factors responsible for transmitting hepatitis C in adultswere infections/transfusions (42%) followed by dental procedures (25%) and surgical scars(23%).
Estilos ABNT, Harvard, Vancouver, APA, etc.
Mais fontes

Teses / dissertações sobre o assunto "Hepatitis C"

1

Pajenčkovskytė, Karolina. "Sergančiųjų lėtiniu virusiniu C hepatitu genotipai". Master's thesis, Lithuanian Academic Libraries Network (LABT), 2004. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2004~D_20040608_165139-44050.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Berg, Thomas. "Chronische Hepatitis C". Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/13812.

Texto completo da fonte
Resumo:
Die vorliegende Habilitationsschrift befasst sich schwerpunktmäßig vor allem mit der Klinik und Therapie der Hepatitis C. Evaluiert wurden: 1. verschiedene therapeutische Strategien, 2. die Ursachen der "Non-Response" auf eine anti-virale Therapie sowie 3. die klinische Relevanz der neu entdeckten Hepatitis-assoziierten Viren und 4. ihre Bedeutung bei Patienten mit akuter bzw. chronischer Lebererkrankung unklarer Ätiologie sowie bei Patienten vor und nach Lebertransplantation. Ad 1. Aus dem Vergleich verschiedener Therapie-Konzepte wie der Kurzzeit- Kombinationstherapie, Triple-Therapie, Hochdosis-Interferon?-Therapie und der Anwendung antiviraler Substanzen wie Ribavirin und Amantadin ergaben sich neue Erkenntnisse hinsichtlich relevanter prognostischer Parameter für die Therapieresponse. Ad 2. Analysiert wurden die möglichen molekularen Mechanismen der Therapieresponse bzw. Non-Response sowie der Stellenwert von Interaktionen bestimmter HCV-Proteine (NS5A, E2, sogenannte PKR-eIF2a Phosphorylisations-Homologie-Domäne [PePHD]) mit den Interferon? induzierten Effektorproteinen. Es konnte gezeigt werden, daß die Anzahl der Mutationen innerhalb des NS5A Proteins einen prognostischen Parameter darstellen hinsichtlich der Response auf eine Interferon?-Therapie. Dagegen spielen Mutationen innerhalb der PePHD-Region keine Rolle. Ad 3. Aus den Untersuchungen zur klinischen Relevanz der neu entdeckten Hepatitis-assoziierten Viren GB Virus-C/Hepatitis G Virus (GBV-C/HGV) und TT-Virus (TTV) ergaben sich keine Hinweise bzgl. eines Einflusses von GBV-C/HGV bzw. TTV-Infektionen auf den Verlauf der chronischen Hepatitis C. Die durchgeführten Verlaufsuntersuchungen bei koinfizierten Patienten sprechen dafür, daß es sich um Interferon-sensitive Viren handelt; jedenfalls beeinflussen sie nicht die IFN?-induzierte Response. Ad 4. Untersucht wurden ferner die Prävalenz, Transmission und Relevanz der GBV-C/HGV und TTV-Infektion im Hinblick auf ihre Hepatitis-induzierenden Eigenschaften. Die Ergebnisse belegen, dass beide Viren parenteral übertragen werden, und dass sie eine hohe Prävalenz bei Patienten mit parenteralen Risikofaktoren besitzen. Eine Hepatitis-induzierende Potenz dieser Viren konnten wir nicht beobachten; bei der Mehrzahl aller chronisch infizierter Personen ließen sich keine Zeichen einer chronischen Hepatitis finden.
The major goal of this thesis is the analysis of the clinical outcome of patients with Hepatitis C virus (HCV) infection and the response to therapy. Analysed were 1. different types of therapeutic strategies 2. causes responsible for ineffective antiviral therapy (non-response) 3. clinical relevance of the newly discovered hepatitis-associated viruses and 4. the role of these viruses in patients with acute or chronic hepatitis of unknown causes and in those receiving liver grafts. Ad 1. Compared were different therapeutic concepts such as short-term combination therapy, triple-therapy, high dose IFN?-therapy and the use of antiviral substances such as ribavirin and amantadine. It emerged that relevant prognostic parameters can be deduced with respect to the therapeutic response rate. Ad 2. Analysed were possible molecular mechanisms, which may interfere with response or non-response to antiviral therapy. In this respect, we focussed on the interaction of certain HCV-proteins as NS5A, E2, so-called PKR-eIF2a phosphorylisation-homology-domain (PePHD). with the interferon-?-induced effector proteins. There is evidence, that number of mutations within the NS5A proteins are of prognostic relevance with respect to the response to interferon?-therapy. In contrast, mutations within the PePHD-region do not play any role in this respect. Ad 3. We also studied the clinical relevance of the newly discovered viruses GBV-C/HGV and TTV, and found, that they have no impact concerning the course of chronic hepatitis C. These viruses are interferon-sensitive and do not influence the IFNa-response as it could be documented by following the course of co-infected patients. Ad 4. Our studies also focused on the prevalence, transmission and relevance of GBV-C/HGV and TTV infections with respect to their role as hepatitis-inducing agents. We can show that both virus types are parenterally transmitted. There is a high prevalence for both types in patients confronted with risk factors for parenteral factors. From analysis of many patients being chronically infected with these viruses it became quite clear that they lack any important potency to provoke chronic liver disease.
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Silva, Filho Hermes Pedreira da. "Estudo Molecular dos Vírus B e C das Hepatites nas Regiões Norte e Nordeste do Brasil". reponame:Repositório Institucional da FIOCRUZ, 2010. https://www.arca.fiocruz.br/handle/icict/4219.

Texto completo da fonte
Resumo:
Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-07-19T21:21:54Z No. of bitstreams: 1 Hermes Pedreira EStudo molecular dos vírus B e C...2010.pdf: 5589974 bytes, checksum: b86706272dbb22d0d349edae7d641ce1 (MD5)
Made available in DSpace on 2012-07-19T21:21:54Z (GMT). No. of bitstreams: 1 Hermes Pedreira EStudo molecular dos vírus B e C...2010.pdf: 5589974 bytes, checksum: b86706272dbb22d0d349edae7d641ce1 (MD5) Previous issue date: 2010
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil
Infecções pelos vírus B e C das hepatites constituem um significante problema de saúde pública em todo mundo. Mais de 350 milhões de pessoas estão cronicamente infectadas pelo VHB e 170 milhões pelo VHC. No Brasil, a prevalência de pessoas infectadas pelo VHB varia de baixa endemicidade (<2%) até alta, (>7%), e estima-se que 1,5% da população esteja infectada pelo VHC (WHO). Estudos recentes tem demonstrado consideráveis variações entre os isolados do VHB, confirmando a diversidade de genótipos do vírus circulantes e o surgimento de mutações no genoma viral que podem ter impacto na resposta terapêutica e imune. Informações sobre a diversidade genética do VHB serão de grande valor para determinar fatores de risco associados a disseminação do vírus e auxiliar na adoção de medidas de prevenção e terapêutica. A infecção pelo VHC tornou-se um sério problema de saude pública desde que não existe uma vacina disponível e o tratamento é extremamente caro para os órgãos públicos como desgastante para o paciente. Este trabalho utilizou as ferramentas moleculares e de epidemiologia no estudo destes vírus para caracterizar molecularmente os vírus B e C das hepatites nas Regiões Norte e Nordeste, particularmente na Bahia, através de sequenciamento de DNA e análises filogenéticas. Amostras de pacientes provenientes da Bahia, Acre, Rondonia, Amazonas, Maranhão e Tocantins foram analisadas. As amostras foram oriundas de outros estudos e de centros de referência para tratamento das hepatites, sendo avaliadas 635 amostras para o VHC e 335 de VHB. Sequencias das regiões pré-S/S e pré- Core/Core do VHB e NS5b, 5UTR, E1 e Core do VHC foram utilizadas para classificação genotípica e análise filogenetica. Os genótipos mais frequentes para o VHB foram A (57%), D (10%) e F(33%) na Bahia e nas amostras da região Norte. Nós encontramos em nosso estudo 55,6% de pacientes co-infectados com VHB/Delta. Não foi possível estabelecer uma ligação genótipo específico com a evolução da infecção, e determinar a presença de mutantes relacionados à resposta terapêutica e ao escape imunológico. Com relação ao VHC, a subtipagem dos isolados foi realizada através do sequenciamento da região NS5b e 5UTR (n=230). Os sub-genótipos mais frequentes foram 1a(45,6%), 1b (46,9%), 3a (6,5%) e 2a/b(0,8%). As regiões E1 e Core também foram sequenciadas e no futuro serão utilizadas para avaliar possiveis mutações. O presente estudo mostra que a aplicação de protocolos de sequenciamento, bioinformática e filogenia são indispensáveis para a compreensão da epidemiologia molecular dos vírus das hepatites.
Infections with hepatitis B and C viruses constitute a significant public health problem worldwide. More than 350 million people are chronically infected with HBV and 170 million by HCV. In Brazil, HBV remains endemic despite widespread vaccination with prevalence of infection ranging from (<2%) low endemicity, until high (>7%) in different regions. Prevalence of HCV infection in Brazil has been estimated at 1.5%. Recent studies have shown considerable genetic variation among HBV isolates, confirming the diversity of circulating genotypes of the virus and the emergence of mutations in the viral genome that may impact on therapeutic and immune response. Information on the genetic diversity of HBV is useful for molecular epidemiology to determine risk factors associated with the spread of the virus and to inform prevention strategies and for monitoring therapy. Because there is no vaccine available to prevent HCV infection and treatment is extremely expensive for public agencies, HCV is an emerging public health problem. The treatment efficiency is directly related to viral genotype. In this study molecular epidemiology tools were used to characterize HBV and HCV in the North and Northeast, particularly in Bahia, through DNA sequencing and phylogenetic analysis. Samples from Bahia, Acre, Rondônia, Amazonas, Maranhão and Tocantins were analyzed. The samples were collected in collaboration with other studies and centers of references for hepatitis treatments. 635 samples from HCV infected patients and 335 samples from HBV infected were evaluated. Sequences of the regions pre-S / S, HBV core / pre-core, NS5B, 5UTR, HCV Core and E1 were used for genotypic classification and phylogenetic analysis. The most frequent HBV genotypes were A (57%), D (10%) and F (33%) in Bahia and in the samples from the North region. Fifty five percent of the patients from Rondônia were coinfected with HBV and HDV. In this study, we were unable to establish a connection with the particular genotype evolution of the infection and determine the presence of mutants related to therapeutic response and immune escape. In the North region co-infection with HBV genotype F and D virus is strongly associated with poor outcome of the disease as informed by the physicians and literature. Regarding HCV, the subtyping of isolates was performed by sequencing the NS5B region and 5UTR (n=230). The sub-genotypes more frequent were 1a (45.6%), 1b (46.9%), 3a (6.5%) and 2a / b (0.8%). The Core and E1 regions were also sequenced and in the future could be used to evaluate possible mutations. This study shows that the implementation of protocols for sequencing, bioinformatics and phylogenetic are essential for understanding the molecular epidemiology of hepatitis.
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Valente, Vanderleia Barbaro. "Estudo da distribuição dos marcadores sorológicos das hepatites B e C entre doadores de sangue do Hemocentro de Ribeirão Preto, SP". Universidade de São Paulo, 2002. http://www.teses.usp.br/teses/disponiveis/17/17139/tde-29052003-193717/.

Texto completo da fonte
Resumo:
Este estudo, que envolveu todos os doadores de sangue (25.891) que compareceram pela primeira vez ao Hemocentro de Ribeirão Preto, de junho de 1996 a junho de 2001, teve os seguintes objetivos: 1) Estudar a positividade de marcadores sorológicos das hepatites B e C em testes da triagem dos doadores. 2) Analisar o fluxo dos doadores positivos para os marcadores das hepatites B e C ao Ambulatório de Hepatites (AH) do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. 3) Estimar a prevalência de infecção atual ou pregressa pelos vírus das hepatites B e C entre os doadores, através da análise dos resultados de testes confirmatórios para essas doenças. 4) Avaliar a importância da determinação da transaminase glutâmico-pirúvica (TGP) como marcador indireto de infecção pelos vírus das hepatites B e/ou C. Foram levantados dados registrados no Hemocentro, no Núcleo de Vigilância Epidemiológica (NVE) e no AH, coletando-se informações referentes ao doador, ao tipo de doação e ao resultado de teste da triagem sorológica (HBsAg, anti-HBc, anti-HCV, TGP, anti-HIV, anti-HTLV, doença de Chagas e sífilis). Foram estudados ainda: os resultados dos testes de repetição – realizados no Hemocentro – dos doadores positivos para os marcadores das hepatites B e C na triagem sorológica; o comparecimento ao NVE; e a confirmação, no AH, dos resultados para esses marcadores. A população dos doadores foi composta majoritariamente por homens (83,6%) e indivíduos de 26 a 45 anos de idade (64,0%). Predominaram as doações vinculadas (85,4%), e as maiores motivações foram solicitação e estímulo familiar ou de amigos. Os valores da prevalência, nos testes da triagem sorológica, foram iguais a 0,63% (IC95%: 0,54 – 0,72), para o HBsAg e 1,15% (IC95%: 1,02 – 1,28), para o anti-HCV. O total de doadores positivos que deveriam ser avaliados no AH, sofreu uma perda de 55,5% entre os suspeitos de ter hepatite B e de 58,7% entre os suspeitos de ter hepatite C, totalizando 266 doadores perdidos quanto ao acompanhamento. Os valores da prevalência, nos testes confirmatórios, foram iguais a 0,22% (IC95%: 0,16 – 0,28), para a hepatite B, e 0,31% (IC95%: 0,24 – 0,38), para a hepatite C. As co-positividades entre os valores de TGP e os marcadores de hepatites, nos testes de triagem sorológica, foram de 8,8%, para o vírus C, e de 0,5%, para o vírus B, indicando que a determinação dessa enzima não auxilia na seleção de doadores em bancos de sangue.
This study, which involved all blood donors (25.891) that attended the Blood Center of Ribeirão Preto for the first time from June 1996 to June 2001 had the following objectives: 1) To study the positiveness for hepatitis B and C serologic markers in donors screening tests. 2) To analyze the flow of positive donors for hepatitis B and C markers to the Hepatitis Ambulatory (HA) in the Clinical Hospital of the Faculty of Medicine of Ribeirão Preto of the University of São Paulo. 3) To estimate the predominance of present or former infection by hepatitis B and C viruses among donors, by analyzing results of screening tests that confirm these diseases. 4) To evaluate the importance of determining the glutamic-piruvic transaminase (GTP) as an indirect marker of infection by hepatitis B and C viruses. Registered data from the Blood Center as well as from the Epidemiological Surveillance Nucleus (ESN) and HA were used with the purpose of collecting information about donors, type of donation and results in serologic screening tests (HBsAg, anti-HBc, anti-HCV, GTP, anti-HIV, anti-HTLV, Chagas disease and syphilis). In addition, a study was performed on the results in repetition tests – that took place in the Blood Center – of positive donors for hepatitis B and C markers in serologic tests as well as on their attendance at the ESN and the confirmation in the HA of the results for these markers. The population of donors was composed in its majority by men (83,6%) and individuals from 26 to 45 year-old (64,0%). Linked donations predominated (85,4%), and the greatest reasons for donation arose from solicitation and stimulus coming from family and friends. The value of prevalence in serologic screening tests was 0,63% (IC95%: 0,54 – 0,72) for HBsAg and 1,15% (IC95%: 1,02 – 1,28) for anti-HCV. The total of positive donors that should have been evaluated in the HA suffered a loss of 55,5% among the suspects of having hepatitis B and of 58,7% among the suspects of having hepatitis C, reaching a total of 266 donors lost during follow-up. The value of prevalence in confirmatory tests was 0,22% (IC95%: 0,16 – 0,28) for hepatitis B and 0,31% (IC95%: 0,24 – 0,38) for hepatitis C. The copositiveness between GPT and hepatitis markers in serologic screening tests was 8.8% for hepatitis C virus and 0.5% for hepatitis B virus, indicating that determination of this enzyme is not helpful in selection of donors in blood banks.
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Silva, Edvaldo Ferreira da. "Prevalência de marcadores sorológicos das hepatites A e B em pacientes com hepatite C crônica atendidos no ambulatório de hepatites do serviço de Gastroenterologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-04022015-153903/.

Texto completo da fonte
Resumo:
Introdução: Pacientes com infecção crônica pelo VHC e superinfecção pelo vírus da hepatite A (VHA) ou o vírus da hepatite B (VHB), têm maior morbi-mortalidade quando comparados com pacientes que apresentam infecção aguda somente pelo VHA ou VHB. A mortalidade associada à hepatite A aguda pode estar particularmente elevada em pacientes com pré-existência de hepatite crônica causada pelo VHC. Por esta razão, a imunização ativa com vacinas contra o VHA e o VHB vem a ser obrigatória nesta população, e consequentemente esta sorologia deve ser determinada. Objetivos: O objetivo deste trabalho foi avaliar a prevalência de marcadores sorológicos da hepatite A e hepatite B em 1.000 pacientes com infecção crônica pelo VHC atendidos no Ambulatório de Hepatites da Divisão de Gastroenterologia e Hepatologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Resultados: O anti-VHA IgG foi positivo em 923 de 1000 pacientes (92,3%). Quando estratificados por idade, o anti-VHA IgG foi encontrado em 61% dos pacientes entre 20 e 29 anos, 70% entre 30 e 39 anos, 85% entre 40 e 49 anos, 94% entre 50 e 59 anos e 99% nos pacientes com mais de 60 anos . O anti-HBc total foi positivo em 244 pacientes (24%). Estratificados por idade, em 4,3% dos pacientes entre 20 e 29 anos, 17% entre 30e 39 anos, 21% entre 40 e 49 anos, 24% entre 50 e 59 anos, e 28% dos pacientes com mais de 60 anos. Dos 244 pacientes anti-HBc IgG positivos, 0,8% são HBsAg positivo, 8,5% anti-HBc IgG isolado e 16% anti-HBs positivo. Conclusões: A prevalência de anti-VHA IgG nod nossos pacientes com hepatite C crônica foi semelhante à da população geral no município de São Paulo. No entanto, o anti-HBc totaI foi maior em nossos pacientes, quando comparada historicamente à população geral dos países ocidentais, sugerindo fatores de risco semelhantes para as hepatites B e C, o que enfatiza a importância dos programas de imunização nesta população
Background and Aims: Patients with chronic HCV and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV. For this reason, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Methods: 1.000 chronic HCV infected patients at the University of Sao Paulo School of Medicine outpatient Liver Clinic were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 923 of 1000 patients (92.3%). When stratified by age, the anti-HAV IgG was found in 61% of patients between 20-29 years, 70% between 30-39 years, 85% between 40-49 years, 94% between 50-59 years, and 99% over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, anti-HBc IgG was found in 4.3% of patients between 20-29 years, 17% between 30-39 years, 21% between 40 -49 years, 24% between 50-59 years, and 28% of patients over 60 years of age. Of the 244 anti-HBc IgG positive patients, 0.8% were also HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: The prevalence of anti-HAV IgG was similar to the general population in the city of São Paulo. However, anti-HBc IgG was higher in our chronic HCV patients, when compared historically to the general population of western countries, suggesting similar risk factors for HBV and HCV acquisition, so emphasizing the importance of immunization programs in this population. Keywords: Hepatitis C, Chronic; Hepatitis C; Hepacivirus, Prevalence; Hepatitis A; Hepatitis B Título: Prevalência de Marcadores Sorológicos das Hepatites A e B em Pacientes com Hepatite C Crônica atendidos no Ambulatório de Hepatites do Serviço de Gastroenterologia Clínica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP Background and Aims: Patients with chronic HCV and superinfection by hepatitis A virus (HAV) or hepatitis B virus (HBV) have higher morbidity and mortality when compared with those without HCV. For this reason, HAV and HBV active immunization has become mandatory in this population and hence their serological markers must be determined. The aim of this study was to evaluate the prevalence of serological markers of HAV and HBV infection in patients with chronic HCV. Methods: 1.000 chronic HCV infected patients at the University of Sao Paulo School of Medicine outpatient Liver Clinic were evaluated for the prevalence of serological markers of HAV and HBV infection. Results: Anti-HAV IgG was positive in 923 of 1000 patients (92.3%). When stratified by age, the anti-HAV IgG was found in 61% of patients between 20-29 years, 70% between 30-39 years, 85% between 40-49 years, 94% between 50-59 years, and 99% over 60 years of age. Anti-HBc IgG was positive in 244 patients (24%). Stratified by age, anti-HBc IgG was found in 4.3% of patients between 20-29 years, 17% between 30-39 years, 21% between 40 -49 years, 24% between 50-59 years, and 28% of patients over 60 years of age. Of the 244 anti-HBc IgG positive patients, 0.8% were also HBsAg positive, 8.5% were anti-HBc IgG isolated and 16% were also anti-HBs positive. Conclusions: The prevalence of anti-HAV IgG was similar to the general population in the city of São Paulo. However, anti-HBc IgG was higher in our chronic HCV patients, when compared historically to the general population of western countries, suggesting similar risk factors for HBV and HCV acquisition, so emphasizing the importance of immunization programs in this population
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Thiel, Jens. "Einfluss von Immunsuppression auf Hepatitis-C-assoziierte Immunphänomene und Hepatitis-C-Quasispezies". [S.l.] : [s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=969417918.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Shen, Hong. "Hepatitis C infection models". Thesis, Paris 5, 2012. http://www.theses.fr/2012PA05T016.

Texto completo da fonte
Resumo:
L'hépatite C (VHC) est l'une des causes principales de maladies du foie dans le monde, qui représentent un risque élevé d'évoluer vers la cirrhose et le carcinome hépatocellulaire. Actuellement, le traitement standard de l’infection par le VHC est l'interféron pégylé-(peg-IFN) et la ribavirine. Bien que le taux de la réponse virale soutenue (RVS) au traitement se soit améliorée au cours de ces années, cette thérapie n'est pas efficace chez tous les patients. En outre, plusieurs effets secondaires toxiques, de complications et le coût élevé limitent la compliance du patient et l'efficacité du traitement. Il n'existe pas de modèle simple d'infection par le VHC et il est nécessaire de développer des modèles in vitro et in vivo utiles pour étudier la physiopathologie de l'infection par le VHC, y compris les événements précoces de l'infection aiguë (l'entrée du virus, des mécanismes immunologiques et génétiques prédictifs) ainsi que l'évaluation de la puissance des médicaments antiviraux contre le VHC. Nous rapportons ici, nos efforts visant à développer des modèles appropriés de l'infection par le VHC. Dans un premier temps, nous avons établi un modèle de petit animal pour étudier l'infection par le VHC. Tupaia est un petit animal, apparenté aux primates et peu couteux. Dans notre travail, nous avons étudié la susceptibilité du tupaia à l'infection par VHC. Douze tupaias adultes ont été inoculés avec le VHC provenant de sérum de patient et d'ARN du VHC (génotype 1a). Trois jeunes tupaias ont été artificiellement nourris pendant un mois et ensuite inoculés par le VHC provenant de sérum du patient. L'ARN du VHC, les anticorps anti-VHC et l’évolution des quasi-espèces du VHC ont été déterminées chez l'animal avant et après l'inoculation. L'infection transitoire et intermittente s'est produite chez deux des 3 jeunes tupaias et l’infection chronique par le VHC s’est produite chez quatre tupaias sur 12 tupaias adultes. Le tupaia devrait représenter un modèle utile pour l'étude de l’infection chronique par le VHC. Dans une deuxième étape, un système de culture in vitro d'hépatocytes primaires de Tupaia a été établi, dans lequel l'infection par le VHC ne pouvait être bloquée ni par le CD81 soluble ni par des anticorps dirigés contre le CD81. Pour comprendre ces résultats, nous avons cloné, séquencé la grande boucle extracellulaire (LEL) du CD81 chez le Tupaia et analysé l'interaction de la protéine d’enveloppe E2 du VHC avec la LEL du CD81 chez le Tupaia par un test « enzyme-linked immunosorbent assay » (EIA). Nous avons constaté que chez le Tupaia, la séquence d'acides aminés du LEL de CD81 qui se lie au VHC présentait en 6 résidus d'acides aminés différents par rapport à la séquence humaine et la capacité de LEL de CD81 à se lier à la proteine d’enveloppe E2 du VHC a également diminuée. La structure différente de CD81 chez l’homme et chez le tupaia pourrait expliquer l'altération de l'interaction entre CD81 et la proteine E2 du VHC. Ce résultat démontre un rôle important de LEL du CD81 pour l'entrée du VHC. Dans une troisième étape, nous avons développé un modèle ex vivo de culture de tranches de foie humain et leur infection par le VHC. Le développement de lignées cellulaires provenant d’hepatocarcinome, permissives à la réplication du VHC, a fourni d'importants nouveaux outils virologiques pour étudier les mécanismes de l'infection par le VHC, mais ce modèle expérimental reste relativement éloigné des conditions physiologiques et pathologiques. Nous rapportons ici le développement d'un nouveau modèle ex vivo utilisant la culture de tranches de foie humain adulte, démontrant, pour la première fois, la capacité d’isolats primaires ainsi que JFH -1, H77/C3, Con1/C3 (HCVcc), de répliquer et de produire de novo des particules virales infectieuses ayant un titre viral élevé…
Hepatitis C virus (HCV) is one of the major causes of liver disease all over the world which has a high risk to progress to cirrhosis and hepatocellular carcinoma. Currently, the licensed standard treatment of HCV infection is Pegylated-interferon (peg-IFN) and ribavirin. Although the sustained viral response (SVR) rate of treatment has improved during these years, this therapy is not effective in all patients. In addition, several toxic side effects, complication and high cost limit the patient compliance and the efficacy of the treatment. There is no easy model of HCV infection and it is necessary to develop useful in vitro and in vivo models to study the pathobiology of HCV infection, including early events of acute infection (viral entry, immunological mechanisms, and genetic predictors) as well as the evaluation of the potency of the HCV antiviral drugs. We report here in our efforts in developing suitable models of HCV infection. In a first step, we preliminary established a small animal model to study HCV infection. Tupaia is a small, closed related to primate and cost-effective animal. In our work, we investigated the susceptibly of tupaia to HCV infection. Twelve adult tupaias were inoculated with native HCV from patient serum and full-length HCV RNA (Genotype 1a). Three young tupaias were artificially breeded for a month and then inoculated by native HCV from patient serum. HCV RNA, anti-HCV and HCV quasi species evolution were determined in the animal before and after inoculation. Transient and intermittent infection occurred in two among 3 young tupaias and HCV chronic infection occurred in four among 12 adult tupaias. Tupaia should represent a useful model for study HCV chronic infection. In a second step, an in vitro culture system of primary tupaia hepatocytes has been established in which HCV infection could be blocked neither by the soluble CD81 nor by antibodies against CD81. To understand these results, we cloned, sequenced the large extracellular loop (LEL) of tupaia CD81 and analyzed the interaction of HCV E2 with the tupaia CD81 LEL by enzyme-linked immunosorbent assay (EIA). We found that in the tupaia the amino acids sequence of HCV CD81 LEL presented in 6 different amino acid residues compared with human CD81 LEL sequence and the CD81 LEL ability to bind to HCV E2 was also decreased. The different structure of CD81 between human and tupaia could explain the alteration of the interaction between HCV E2 and CD81. This result demonstrated an important role of CD81 LEL for HCV entry. In a third step, we developed an ex vivo model of human liver slices culture and their infection with HCV. The development of human cultured HCV-replication-permissive hepatocarcinoma cell lines has provided important new virological tools to study the mechanisms of HCV infection; however this experimental model remains distantly related to physiological and pathological conditions. Here, we report the development of a new ex vivo model using human adult liver slices culture, demonstrating, for the first time, the ability of primary isolates to undergo de novo viral replication with the production of high titer infectious virus, as well as JFH-1, H77/C3, Con1/C3 (HCVcc). This experimental model was validated by demonstrating the HCV neutralization or HCV inhibition, in a dose-dependent manner, either by CD81 or E2 specific antibodies or convalescent serum from a recovered HCV patient, or by anti-viral drugs. This new ex vivo model represents a powerful tool for studying the viral life cycle, dynamics of virus spread in the liver and also for evaluating the efficacy of the new antiviral drugs. In the last step, we evaluated the efficacy of the new antiviral drugs with our ex vivo model of human adult liver slices. HCV NS3/4A protease is essential for viral replication and has been one of the most important target for developing specific antiviral drug
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Hopwood, Maxwell Norman. "Living with Hepatitis C". Maastricht : Maastricht : Universiteit Maastricht ; University Library, Universiteit Maastricht [host], 2007. http://arno.unimaas.nl/show.cgi?fid=9171.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Montes, Teves Pedro. "Hepatitis C: retos pendientes". Sociedad de Gastroenterología del Perú, 2014. http://hdl.handle.net/10757/331937.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Winckler, Fernanda Cristina. "Influência da Resposta inflamatória na resposta virológica sustentada em pacientes com hepatite C crônica genótipo 1 durante o tratamento antiviral com terapia tripla". Botucatu, 2016. http://hdl.handle.net/11449/144991.

Texto completo da fonte
Resumo:
Orientador: Giovanni Faria Silva
Coorientador: Marjorie de Assis Golim
Resumo: A hepatite C é uma doença infecciosa que torna-se crônica em cerca de 85% dos infectadosque poderão desenvolver cirrose e carcinoma hepato celular. O tratamento antiviral em muitosdos pacientes não é eficaz, principalmente quando estes portam o genótipo 1 e fibroseavançada, a resposta inflamatória também desempenha seu papel sobre a resposta virológicasustentada (RVS) durante o tratamento com Interferon Peguilado (PegIFN) associado aRibavirina (RBV). Nesse estudo nosso objetivo principal foi avaliar a influência da respostainflamatória através de células e citocinas/quimiocinas sobre a resposta virológica do pacienteem tratamento antiviral com terapia tripla. Incluimos pacientes com RNA VHC+, nuncatratados (naive), portadores do genótipo 1, ambos os sexos e com fibrose avançada F3 (n=6);F4 (n=21) candidatos ao tratamento em regime triplo. Os pacientes tiveram suas amostrascoletadas e analizadas nas semanas 0 e 12 do tratamento e os seguintes parâmetros foramanalisados: IL-2, IL-4, IL-6, IL-8, IL-10, IL-17A, TNF-α, IFN-γ, RANTES, MCP-1, MIG, IP-10, através de citometria de fluxo (método CBA). Foram incluídos 15 voluntários saudáveis(grupo controle) e 27 pacientes que foram separados em G1(RVS) e G2 (não RVS), a taxa deRVS foi de 63%. Os pacientes com hepatite C crônica tiveram os níveis circulantes de IP10,MCP-1, MIG, RANTES, IL-8 e IL-6 mais elevados quando comparados com voluntáriossaudáveis, quando comparados G1xG2 os níveis de RANTES (p=0,04... (Resumo completo, clicar acesso eletrônico abaixo)
Mestre
Estilos ABNT, Harvard, Vancouver, APA, etc.
Mais fontes

Livros sobre o assunto "Hepatitis C"

1

Askari, Fred K. Hepatitis C, the silent epidemic: The authoritative guide. Cambridge, Mass: Perseus, 2001.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Askari, Fred K. Hepatitis C, the silent epidemic: The authoritative guide. New York: Plenum Trade, 1999.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Sawyer, Forrest. Hepatitis C. Princeton, N.J: Films for the Humanities & Sciences, 2003.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

England, Health Promotion, ed. Hepatitis C. London: Health Promotion England, 2000.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

R, Foster G., ed. Hepatitis C. London: Baillière Tindall, 2000.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

National Institute on Drug Abuse, ed. Hepatitis C. Bethesda, MD (6001 Executive Blvd., Bethesda 20892): National Institute on Drug Abuse, U.S. Dept. of Health and Human Services, National Institutes of Health, 2000.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Canada. Library of Parliament. Parliamentary Research Branch. Hepatitis C. Ottawa: Library of Parliament, 1999.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Ozaras, Resat, e Dominique Salmon-Ceron, eds. Viral Hepatitis: Chronic Hepatitis C. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

N, Lau Johnson Y., ed. Hepatitis C protocols. Totowa, N.J: Humana Press, 1998.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

W, Reesink H., ed. Hepatitis C virus. 2a ed. Basel: Karger, 1998.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Mais fontes

Capítulos de livros sobre o assunto "Hepatitis C"

1

Arends, Joop E., Maria Cristina Leoni e Dominique Salmon. "Acute Hepatitis C". In Viral Hepatitis: Acute Hepatitis, 45–65. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03535-8_4.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Arends, Joop E., Maria Cristina Leoni e Dominique Salmon-Ceron. "Acute Hepatitis C". In Viral Hepatitis: Chronic Hepatitis C, 197–217. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_11.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Korn, Klaus. "Hepatitis C". In S2k-Leitlinie - Labordiagnostik schwangerschaftsrelevanter Virusinfektionen, 133–43. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43481-9_13.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Dusheiko, Geoffrey. "Hepatitis C". In Sherlock's Diseases of the Liver and Biliary System, 436–67. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119237662.ch23.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Fried, Michael W., Jama M. Darling e Stanley M. Lemon. "Hepatitis C". In Schiff's Diseases of the Liver, 628–98. Oxford, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119251316.ch25.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Kanto, Tatsuya, e Sachiyo Yoshio. "Hepatitis C". In Liver Immunology, 273–86. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-51709-0_17.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Dusheiko, Geoffrey. "Hepatitis C". In Sherlock's Diseases of the Liver and Biliary System, 406–26. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444341294.ch20.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Charlton, Michael, e Travis Dick. "Hepatitis C". In Practical Gastroenterology and Hepatology Board Review Toolkit, 480–86. Oxford, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781119127437.ch77.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Sainburg, Robert L., Andrew L. Clark, George E. Billman, Zachary J. Schlader, Toby Mündel, Kevin Milne, Earl G. Noble et al. "Hepatitis C". In Encyclopedia of Exercise Medicine in Health and Disease, 408. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_2485.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Darling, Jama M., Stanley M. Lemon e Michael W. Fried. "Hepatitis C". In Schiff's Diseases of the Liver, 582–652. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781119950509.ch25.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "Hepatitis C"

1

Ekmen, Onder. "A Case of Fulminant Hepatitis B Reactivation After Hepatitis C Treatment in Hepatitis B+C Co-infection". In 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0042-1760078.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Prasetia Nurwidda, Arvi Dian, Poernomo Boedi Setiawan, Iswan Abbas Nusi, Herry Purbayu, Titong Sugihartono, Ummi Maimunah, Ulfa Kholili et al. "Thrombocytopenia in Chronic Hepatitis C". In Surabaya International Physiology Seminar. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007340404460452.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

López, Sandra, Itxaso Respaldiza e Ander Portugal. "Hepatitis C, el enemigo silencioso". In XXIX Congreso Nacional de Medicina General y de Familia y V Jornadas SEMG Andalucía. Grupo Pacífico, 2023. http://dx.doi.org/10.48158/semg23-611.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Chawathe, Sudarshan S. "Diagnostic Classification Using Hepatitis C Tests". In 2020 IEEE International IOT, Electronics and Mechatronics Conference (IEMTRONICS). IEEE, 2020. http://dx.doi.org/10.1109/iemtronics51293.2020.9216446.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Shahzadi, Mehreen, Faisal Bukhari e Numan Shafi. "Intelligent Predictive Model for Hepatitis C". In 2023 3rd International Conference on Artificial Intelligence (ICAI). IEEE, 2023. http://dx.doi.org/10.1109/icai58407.2023.10136685.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Paschoini, MC, LN Resende, MM Mendonça, GPM Gomide e JU Ribeiro. "P3.181 Hepatitis c: challenging modern obstetrics". In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.416.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Eid, Fatma Elzahraa, Haitham Elmarakeby, Lenwood Heath e Mahmoud ElHefnawi. "Human microRNAs targeting hepatitis C virus". In 2014 Middle East Conference on Biomedical Engineering (MECBME). IEEE, 2014. http://dx.doi.org/10.1109/mecbme.2014.6783236.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Nandian Saputra, Trimardi Aditya, Ken Indiana Arizona, Muhammad Rizky Andrian, Felix Indra Kurniadi e Budi Juarto. "Random Forest in Detecting Hepatitis C". In 2022 9th International Conference on Information Technology, Computer, and Electrical Engineering (ICITACEE). IEEE, 2022. http://dx.doi.org/10.1109/icitacee55701.2022.9924074.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Kchir, H., D. KAFFEL, H. Dabbebi, D. ISSAOUI, H. Sahli, W. Hamdi, M. Elleuch, M. M. Kchir, R. Debbeche e N. Maamouri. "AB1049 Rheumatological manifestations during chronic hepatitis c". In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5886.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Matthews, Charmaine, Helen Caldwell, Eimear Kealey, Elliot Graves, Michael Jones, David Byrne e Paul Richardson. "OP28 Hepatitis C – the male prisoner’s perspective". In Abstracts of the British Association for the Study of the Liver Annual Meeting, 20–23 September 2022. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2022. http://dx.doi.org/10.1136/gutjnl-2022-basl.41.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.

Relatórios de organizações sobre o assunto "Hepatitis C"

1

Kuypers, Marshall A., Gregory Joseph Lambert, Thomas W. Moore, Glass, Robert John,, Patrick D. Finley, David Ross e Maggie Chartier. Modeling Hepatitis C treatment policy. Office of Scientific and Technical Information (OSTI), setembro de 2013. http://dx.doi.org/10.2172/1096266.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Sjogren, Maria H., e Kent Holtzmuller. Hepatitis C Virus Infection: Mechanism of Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2001. http://dx.doi.org/10.21236/ada406083.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Sjogren, Maria H. Hepatitis C. Virus Infection: Mechanism of Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2004. http://dx.doi.org/10.21236/ada433067.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Sjogren, Maria H., e Brooke Huntley. Hepatitis C. Virus Infection: Mechanisms of Disease Progression. Fort Belvoir, VA: Defense Technical Information Center, outubro de 2007. http://dx.doi.org/10.21236/ada477987.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Adebiyi, Sadiat, Sakinah Shaw e Tracy McClinton. Annual Hepatitis C Screening QI: A Scoping Review. University of Tennessee Health Science Center, abril de 2022. http://dx.doi.org/10.21007/con.dnp.2022.0026.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Adebiyi, Sadiat, Sakinah Shaw e Tracy McClinton. Annual Hepatitis C Screening QI: A Scoping Review. University of Tennessee Health Science Center, abril de 2022. http://dx.doi.org/10.21007/con.dnp.2022.0026.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Koizumi, Yoshiki, Syo Nakajim, Hirofumi Ohash, Yasuhito Tanaka, Takaji Wakita, Alan S. Perelson, Shingo Iwami e Koichi Watashi. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Office of Scientific and Technical Information (OSTI), março de 2016. http://dx.doi.org/10.2172/1242919.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Nelson, David, Michael Fried, Mark Sulkowski, Donna Evon, Jodi Segal, Anna Lok, Paul Stewart_ Stewart et al. Comparing Oral Medicines to Treat Hepatitis C Virus -- The PRIORITIZE Study. Patient-Centered Outcomes Research Institute® (PCORI), março de 2022. http://dx.doi.org/10.25302/03.2022.hpc.150327891.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin e Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, julho de 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Texto completo da fonte
Resumo:
Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplementary Concept] ) OR ((lipoprotein cholesterol) OR ("lipidemia") OR (lipid metabolism) OR (lipid)). Information sources: We conducted a comprehensive literature search of PubMed, Cochrane Library, Embase, and Ovid MEDLINE electronic databases from their inception to May 20, 2022.
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Nguyen, Tung, Mandana Khalili, Janice Tsoh, Judith Walsh, Elizabeth Goldman, Arcadi Kolchak, Ginny Gildengorin, Ching Wong e Ivy Lau. Comparing Ways to Increase Hepatitis B and C Screening Among Asian Americans. Patient-Centered Outcomes Research Institute® (PCORI), março de 2020. http://dx.doi.org/10.25302/02.2020.ad.12114615.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Você também pode estar interessado nas extensas listas de trabalhos sobre o assunto "Hepatitis C":
Artigos de revistas Teses / dissertações Livros
Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!

Vá para a bibliografia